- $631.35m
- $519.81m
- $311.71m
Brief: Cormedix Announces Completion Of Enrollment In Phase Iii Respect Clinical Trial For Rezzayo
Brief: Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
Brief: CorMedix Announces Strategic Minority Investment in Talphera
Brief: Cormedix Completes Acquisition Of Melinta Therapeutics, Raises Financial Guidance And Announces New Leadership Team
Brief: CorMedix To Acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence In Acute Care Settings
Biopharma firm CorMedix's Q2 revenue beats estimates, announces acquisition of Melinta Therapeutics
Two US judges withdraw rulings after attorneys question accuracy
U.S. STOCKS ON THE MOVE-Estee Lauder, TC Energy, Cancer test makers
U.S. STOCKS ON THE MOVE- Nuclear stocks, Kymera Therapeutics, Estee Lauder
CorMedix drops as $85 mln stock offering priced
Brief: Cormedix Announces Pricing Of Public Offering Of Common Stock
Brief: CorMedix To Offer And Sell $85 Million In Common Stock
CorMedix falls after unveiling $85 mln stock offering
Brief: CorMedix inc. Announces Customer Implementation
CorMedix Inc expected to post earnings of 25 cents a share - Earnings Preview
Brief: Cormedix To Report First Quarter 2025 Financial Results
U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences
CorMedix Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: CorMedix Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update